The Cancer Center Administration staff is responsible for the administrative, fiscal, information and facilities management that support the research efforts of the Cancer Center. Ms. Janet Villarmia is the chief administrative and financial officer of the USC Norris Comprehensive Cancer Center (NCCC). As the Associate Director for Administration and Education and a senior leader of the Cancer Center, she is a member of the Executive Committee and the Cancer Center Leadership Council. Ms. Villarmia has primary responsibility for the management of the Cancer Center Support Grant (CCSG). She supervises the work of the Cancer Center Business Office and the Cancer Center Administrative Office. Ms. Villarmia's other administrative responsibilities include oversight of the Cancer Research Informatics Core, Facilities Management, the Patient Education and Community Outreach Center, the Cancer Survivorship Advisory Council and membership on the Informatics Working Group. She oversees, in overlap with the other Associate Directors, the operations of the CCSG funded shared resources. The Cancer Center Business Office is responsible for the day-to-day accounting of all the CCSG budgets as well as the management of the research and gift accounts of many of the investigators housed in NCCC space. The office consists of a Senior Business Officer and 5.6 FTE accountants and analysts. The primary business goal of the Cancer Center Business Office is to promote a business environment that maximizes research and minimizes administrative burden for NCCC investigators and lab personnel without compromising solid stewardship of funds. The personnel in the Cancer Center Administrative Office provide administrative and secretarial support to the Cancer Center Director and the various Associate Directors, research program leaders, shared resources directors as well as to various NCCC committees and advisory groups. They organize NCCC seminars, retreats, conferences, meetings, and poster sessions. We are requesting $598,180 in the first year to support the Cancer Center Administration, which represents 20% of the annual total cost of the administration and 9% ofthe total Year 1 CCSG budget.
The Cancer Center Administration fosters the development of more effective prevention, diagnosis, treatment of cancer by providing the administrative, fiscal, information, and facilities management to support the cancer research efforts of NCCC investigators.
|Bensman, Timothy J; Jayne, Jordanna G; Sun, Meiling et al. (2017) Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother 61:|
|Thomas, Duncan C (2017) Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer. Epidemiology 28:470-478|
|Thomas, Duncan C (2017) What Does ""Precision Medicine"" Have to Say About Prevention? Epidemiology 28:479-483|
|Schwitzer, Emily; Orlow, Irene; Zabor, Emily C et al. (2017) No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. Pigment Cell Melanoma Res 30:424-427|
|Okazaki, Satoshi; Stintzing, Sebastian; Sunakawa, Yu et al. (2017) Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer 141:1222-1230|
|Liang, Gangning; Weisenberger, Daniel J (2017) DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics 12:416-432|
|Kim, Yong-Mi; Gang, Eun-Ji; Kahn, Michael (2017) CBP/Catenin antagonists: Targeting LSCs' Achilles heel. Exp Hematol 52:1-11|
|Reid, Brett M; Permuth, Jennifer B; Chen, Y Ann et al. (2017) Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 26:116-125|
|Poulard, Coralie; Bittencourt, Danielle; Wu, Dai-Ying et al. (2017) A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP. EMBO Rep 18:1442-1459|
|Tokunaga, Ryuma; Zhang, Wu; Naseem, Madiha et al. (2017) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev 63:40-47|
Showing the most recent 10 out of 739 publications